RxDoctor Payments Data

Ahmad Alturjuman

Interventional Cardiology · Riverside, CANPI 1114980703

Payments from drug & device makers

$20,808in general payments, 2019–2025

Across 943 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Novartis$2K
  • Medtronic$2K
  • Johnson & Johnson$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Merck$831
  • plus $11K from 41 others

What the payments were for

  • Travel & lodging$1,6648%
  • Food & beverage$18,83291%
  • Education$3132%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,808 in reported general payments places this provider in the 65th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$331,378
Medicare patients
724
Services billed
2,736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban594$550,037
EntrestoSacubitril/Valsartan254$241,527
XareltoRivaroxaban242$207,397
MounjaroTirzepatide65$65,529
FarxigaDapagliflozin Propanediol86$53,116
JardianceEmpagliflozin68$52,657
BrilintaTicagrelor66$51,219
Repatha SureclickEvolocumab61$35,070
OzempicSemaglutide22$24,751
MultaqDronedarone Hcl20$24,689
Ranolazine ErRanolazine159$9,399
Metoprolol Succinate783$8,079
Amiodarone Hcl155$5,878
DapagliflozinDapagliflozin Propanediol13$5,624
Diltiazem 12hr ErDiltiazem Hcl38$5,307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$755$550,037594 claims
NovartisEntresto$2,149$241,527254 claims
Johnson & JohnsonXarelto$1,495$207,397242 claims
AstraZenecaFarxiga, Brilinta$576$104,335152 claims
Lilly USA, LLCMounjaro$155$65,52965 claims
Boehringer IngelheimJardiance$793$52,65768 claims
Novo NordiskOzempic$344$24,75122 claims
Sanofi-aventis U.S. LLCMultaq$500$24,68920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →